Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
BMC Cancer|July 28, 2023
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancerErnest Nadal, Mansoor Saleh, Santiago Ponce Aix, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Clinical Lung Cancer|August 8, 2017
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored TreatmentsJon Zugazagoitia, Daniel Rueda, Nuria Carrizo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 16, 2018
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK StudyDavid R Gandara, Joachim von Pawel, Julien Mazieres, et al.
Clinical Lung Cancer|October 24, 2020
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical TrialDavid R Spigel, Robert M Jotte, Santiago Ponce Aix, et al.
BMC Cancer|February 1, 2018
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in SpainEdurne Arriola, Ramón García Gómez, Pilar Diz, et al.
Cancer|November 2, 2018
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistanceJon Zugazagoitia, Ana Gómez-Rueda, Eloisa Jantus-Lewintre, et al.
The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.
JAMA Oncology|January 13, 2018
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung CancerLaura Mezquita, Edouard Auclin, Roberto Ferrara, et al.
Pageof 11